Thinning revenues: inside the $14bn Eliquis patent cliff
Eliquis (apixaban) is one of the most commercially consequential loss-of-exclusivity (LOE) events in recent pharmaceutical history, with patent expiries expected…
All articles by GlobalData Healthcare
GlobalData Healthcare
-
-
Early detection of bowel Cancer in the UK represents success of screening program
Bowel cancer, also known as colorectal cancer, is the second most lethal cancer after lung cancer, with the highest incidence…
-
Pharma Meets AI Conference 2026: AI in pharma begins delivering measurable ROI
At the Pharma Meets AI conference in Barcelona, Spain, in April 2026, discussions around AI governance highlighted a growing shift…
-
Pharma Meets AI Conference 2026: AI governance shifts to embedded practice
At the Pharma Meets AI conference in Barcelona, Spain, in April 2026, discussions around AI governance highlighted a clear shift…
-
ESCMID Global 2026: Pritelivir excels in immunocompromised refractory HSV patients
At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 conference, Phase III data for Aicuris’s pritelivir,…
-
AAN 2026: Tavapadon post-hoc analysis strengthens its D1/D5 agonist pitch
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, AbbVie presented new results from its post-hoc analysis…
-
AAN 2026: Head-to-head trial shows superiority of Qulipta for migraine prevention
Historically, migraine prevention has been managed with a wide variety of non-migraine-specific drug classes, such as beta-adrenergic receptor blockers, calcium…
-
Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal
On 20 April 2026, Biogen announced that it would acquire exclusive rights to TJ Biopharma’s anti-CD38 immunotherapy, felzartamab, in the…
-
ESCMID Global 2026: Zelicapavir demonstrates benefits for high-risk adults with RSV
At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 conference, Chris Harris from Enanta Pharmaceuticals presented…
-
Pharma Meets AI Conference 2026: Key barriers to scaling AI in drug development
At the Pharma Meets AI conference in Barcelona, Spain, in April 2026, discussions highlighted that while AI adoption in drug…